Letermovir
Letermovir is a pharmaceutical drug with 37 clinical trials. Currently 19 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
10
Mid Stage
16
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
12 of 12 finished
0.0%
0 ended early
19
trials recruiting
37
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
Letermovir for R+ Study
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
Clinical Trials (37)
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
Letermovir for R+ Study
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Letermovir vs Valganciclovir in CMV R+ Kidney Transplant
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Letermovir for CMV Prevention After Lung Transplantation
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1
Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 37